Acumen Pharmaceuticals Inc
ABOS
Company Profile
Business description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Contact
1210-1220 Washington Street
Suite 210
NewtonMA02465
USAT: +1 617 344-4190
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
61
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,897.00 | 59.20 | -0.66% |
| CAC 40 | 8,103.85 | 19.56 | -0.24% |
| DAX 40 | 25,348.16 | 62.47 | -0.25% |
| Dow JONES (US) | 51,511.59 | 352.10 | -0.68% |
| FTSE 100 | 10,714.71 | 9.45 | 0.09% |
| HKSE | 24,761.13 | 72.99 | -0.29% |
| NASDAQ | 26,936.04 | 308.24 | -1.13% |
| Nikkei 225 | 65,513.99 | 495.04 | 0.76% |
| NZX 50 Index | 13,824.83 | 3.07 | 0.02% |
| S&P 500 | 7,706.03 | 58.61 | -0.75% |
| S&P/ASX 200 | 8,702.00 | 63.30 | -0.72% |
| SSE Composite Index | 3,888.37 | 48.15 | -1.22% |